These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 30009714)
1. Study of Adverse Drug Effects of Direct-Acting Antivirals for Chronic HCV Infection at Fayoum Governorate, Egypt - A Pharmacovigilance Study. Ahmed EI; Abdel Wahed WY; Hassan EA; Ahmed TI Curr Drug Saf; 2018; 13(3):187-195. PubMed ID: 30009714 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study. El-Marakby MG; Solayman MH; Sabri NA Ther Innov Regul Sci; 2023 Sep; 57(5):997-1007. PubMed ID: 37227588 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection. Elbaz T; Abdo M; Omar H; Hassan EA; Zaghloul AM; Abdel-Samiee M; Moustafa A; Qawzae A; Gamil M; Esmat G J Med Virol; 2019 Feb; 91(2):272-277. PubMed ID: 30138531 [TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience. Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115 [TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. Doss W; Shiha G; Hassany M; Soliman R; Fouad R; Khairy M; Samir W; Hammad R; Kersey K; Jiang D; Doehle B; Knox SJ; Massetto B; McHutchison JG; Esmat G J Hepatol; 2015 Sep; 63(3):581-5. PubMed ID: 25937436 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. Sulkowski MS; Feld JJ; Lawitz E; Felizarta F; Corregidor AM; Khalid O; Ghalib R; Smith WB; Van Eygen V; Luo D; Vijgen L; Gamil M; Kakuda TN; Ouwerkerk-Mahadevan S; Van Remoortere P; Beumont M J Viral Hepat; 2018 Jun; 25(6):631-639. PubMed ID: 29274193 [TBL] [Abstract][Full Text] [Related]
8. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Poordad F; Schiff ER; Vierling JM; Landis C; Fontana RJ; Yang R; McPhee F; Hughes EA; Noviello S; Swenson ES Hepatology; 2016 May; 63(5):1493-505. PubMed ID: 26754432 [TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India. Shah SR; Chowdhury A; Mehta R; Kapoor D; Duseja A; Koshy A; Shukla A; Sood A; Madan K; Sud R; Nijhawan S; Pawan R; Prasad M; Kersey K; Jiang D; Svarovskaia E; Doehle B; Kanwar B; Subramanian M; Acharya SK; Sarin S J Viral Hepat; 2017 May; 24(5):371-379. PubMed ID: 27933698 [TBL] [Abstract][Full Text] [Related]
10. Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy. Ghanem SE; Elsabaawy M; Shebl N; Abdelsameea E; Othman W; El-Bassal FI; Elgedawy GA; Elsabaawy DM; Helal ML Expert Rev Anti Infect Ther; 2020 Sep; 18(9):947-954. PubMed ID: 32419526 [No Abstract] [Full Text] [Related]
11. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Mangia A; Arleo A; Copetti M; Miscio M; Piazzolla V; Santoro R; Squillante MM Liver Int; 2016 Jul; 36(7):971-6. PubMed ID: 26786792 [TBL] [Abstract][Full Text] [Related]
12. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629 [TBL] [Abstract][Full Text] [Related]
13. Predictors of adverse drug reactions associated with ribavirin in direct-acting antiviral therapies for chronic hepatitis C. Cursino CN; Monteiro PGO; Duarte GDS; Vieira TBQ; Crisante VC; Giordani F; Xavier AR; de Almeida RMVR; Calil-Elias S Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1601-1608. PubMed ID: 31692182 [TBL] [Abstract][Full Text] [Related]
14. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease. García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685 [TBL] [Abstract][Full Text] [Related]
15. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir. Kowdley KV; Nelson DR; Lalezari JP; Box T; Gitlin N; Poleynard G; Rabinovitz M; Ravendhran N; Sheikh AM; Siddique A; Bhore R; Noviello S; Rana K Liver Int; 2016 Nov; 36(11):1611-1618. PubMed ID: 27188960 [TBL] [Abstract][Full Text] [Related]
16. Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). Buti M; Calleja JL; Lens S; Diago M; Ortega E; Crespo J; Planas R; Romero-Gómez M; Rodríguez FG; Pascasio JM; Fevery B; Kurland D; Corbett C; Kalmeijer R; Jessner W Aliment Pharmacol Ther; 2017 Feb; 45(3):468-475. PubMed ID: 27896822 [TBL] [Abstract][Full Text] [Related]
17. Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C. Izzo I; Zanotti P; Chirico C; Casari S; Villanacci V; Salemme M; Biasi L; Festa E; Castelli F Infection; 2016 Dec; 44(6):811-812. PubMed ID: 27311809 [TBL] [Abstract][Full Text] [Related]
18. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C. Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314 [TBL] [Abstract][Full Text] [Related]
19. Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience. Tong MJ; Chang PW; Huynh TT; Rosinski AA; Tong LT J Dig Dis; 2016 Feb; 17(2):113-21. PubMed ID: 26749171 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Welzel TM; Nelson DR; Morelli G; Di Bisceglie A; Reddy RK; Kuo A; Lim JK; Darling J; Pockros P; Galati JS; Frazier LM; Alqahtani S; Sulkowski MS; Vainorius M; Akushevich L; Fried MW; Zeuzem S; Gut; 2017 Oct; 66(10):1844-1852. PubMed ID: 27418632 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]